drugset / Trial / NCT02386098
Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) \[with or without ritonavir (RTV)\] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.
Timeline
- Start
- 2015-07-08
- Primary completion
- 2017-06-07
- Completion
- 2017-06-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atazanavir | Other / unclassified | 300 mg | Oral |
| Subject | Atazanavir | Other / unclassified | 400 mg | Oral |
| Subject | BMS-955176 | Other / unclassified | 120 mg | Oral |
| Subject | BMS-955176 | Other / unclassified | 180 mg | Oral |
| Subject | Tenofovir | Small molecule | 300 mg | Oral |
| Background | Dolutegravir | Other / unclassified | 50 mg | Oral |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |